埃博拉疫苗——我们目前的进展如何？
Ebola vaccines - Where are we?
作者信息
Watle Sara Viksmoen, Norheim Gunnstein, Røttingen John-Arne
机构信息
a Domain for Infection Control and Environmental Health, Norwegian Institute of Public Health , Oslo , Norway.
出版信息
Hum Vaccin Immunother. 2016 Oct 2;12(10):2700-2703. doi: 10.1080/21645515.2016.1217372.
The 2014-16 Ebola outbreak in West Africa has by far been the largest and most devastating Ebola outbreak so far. At the start of the epidemic only 2 Ebola DNA vaccine candidates had been tested in clinical trials and the correlate of protection in humans was unknown. International stakeholders coordinated by the World Health Organization agreed to fast-track the development of 2 Ebola vaccine candidates, based on adenovirus and vesicular stomatitis virus (VSV) vectors. Phase I and II clinical trials were initiated in the autumn of 2014 and found both vaccines to be acceptable for proceeding to phase III trials. Despite the epidemic waning in the spring of 2015, by July 2015 preliminary results from a phase III trial in Guinea proved the Ebola VSV vaccine to be effective.
2014年至2016年在西非爆发的埃博拉疫情是迄今为止规模最大、破坏性最强的埃博拉疫情。在疫情初期，仅有2种埃博拉DNA候选疫苗在临床试验中接受了测试，而且人类的保护相关因素尚不清楚。由世界卫生组织协调的国际利益相关方同意加速研发2种基于腺病毒和水疱性口炎病毒（VSV）载体的埃博拉候选疫苗。2014年秋季启动了I期和II期临床试验，结果发现这两种疫苗都可以进入III期试验。尽管疫情在2015年春季有所缓解，但到2015年7月，在几内亚进行的一项III期试验的初步结果证明埃博拉VSV疫苗是有效的。
Zotero 插件